Kansas Attraction Development Grants

The Biosensing program is part of the Engineering Biology and Health cluster, which also includes 1) the Biophotonics program; 2) the Cellular and Biochemical Engineering program; 3) the Disability and Rehabilitation Engineering program; and 4) the Engineering of Biomedical Systems program. The Biosensing program supports fundamental engineering research in the monitoring, identification and/or quantification of biological analytes and phenomena using innovations that exist at the intersection of engineering, life sciences, and information technology. Projects submitted to the program must advance both engineering and life sciences. The Biosensing program encourages proposals that, in addition to advancing biosensing technology, address critical sensor needs in biomedical research, public health, food safety, agriculture, forensics, environmental protection, and homeland security. Proposals are especially encouraged in areas of critical need: sensing technologies that can enable monitoring and surveillance of the environment and/or individuals for novel infectious agents; platform technologies that can readily be modified as soon as new agents are detected, sequenced, and/or otherwise characterized to enable rapid deployment of sensors in clinics and the environment; and adaptive and/or multiplex sensing technologies that can help the nation prevent the spread of the next global pandemic. Major areas of interest for the program include: -Novel signal transduction principles and mechanisms that enable sensitive and specific biosensors, suitable for measurements in multiple areas; -Design of novel biorecognition elements and appropriately designed transducing systems to enable adaptable and/or reconfigurable operating parameters in response to environmental changes or application needs at levels of device, system, or data analysis; -Development of adaptive and/or evolvable biosensing systems for detection of novel target analytes or analytes under novel conditions; -Novel synthetic biology approaches for the development of cell-free and cell-based biosensors; and -Combining biosensors with artificial intelligence (AI) methods to improve sensor specificity and response time.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same target engagement measure; or study the impact of the natural product in a population that is more responsive,

The Small Business Improvement Fund (SBIF) provides reimbursement grant funding for permanent building improvements and repairs across the city. Offered by the Department of Planning and Development (DPD) to tenants and owners of industrial and commercial properties, SBIF grants are funded by Tax Increment Financing (TIF) revenues in designated TIF districts citywide. Program participants can receive grants to cover between 30 percent and 90 percent of the cost of remodeling work, with a maximum grant of $150,000 for commercial properties and $250,000 for industrial properties. The grant, which is administered by SomerCor on the City’s behalf, does not have to be repaid.

Purpose: The Song-Brown Program funds institutions that train primary care doctors to provide health care in California’s medically underserved areas. Description: This grant opportunity will result in funding organizations to educate and train primary care (family medicine, internal medicine, OB/GYN, and pediatric) residents to work in underserved communities. All residency programs shall incorporate the following strategies into their programs: 1. Providing training sites in medically underserved multi-cultural communities, lower socioeconomic neighborhoods, or rural communities, and preparing primary care physicians for service in such neighborhoods and communities. 2. Establishing procedures to identify, recruit, and match primary care residents who possess characteristics which would suggest a predisposition to practice in areas of unmet need, and who express a commitment to serve in areas of unmet need. 3. Implementing counseling and placement programs to encourage training program graduates to enter practice in areas of unmet need. 4. Providing preceptorship experiences in an area of unmet need to enhance the potential of training program graduates to practice in such an area. Keywords: funding, graduate medical education funding, residency funding, family medicine, internal medicine, obstetrics and gynecology, pediatric

This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials, and to increase their likelihood of success. This could be through the development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.